PROSTATE ADENOCARCINOMA

This study tested whether giving a higher dose of radiation specifically to the visible tumor inside the prostate could improve cancer control in men with localized prostate cancer. Eighty-five men either received a standard radiation plan with an extra boost to the tumor or a co…

This study tested a new type of PET/MRI scan that uses a special tracer to find small spots of prostate cancer that standard scans miss. Men with a rising PSA after prostate surgery and radiation received targeted radiation to those spots. The goal was to see if this approach can…

This early-phase trial tested a shorter course of radiation for men whose prostate cancer came back after their prostate was removed. Instead of the usual 6-7 weeks of daily radiation, researchers gave higher doses over just 2-4 weeks, focusing the strongest radiation on the tumo…

This phase II trial tested a shorter course of higher-dose radiation (hypofractionation) in 53 men with high-risk prostate cancer who had already had their prostate removed. The goal was to see if this approach could control cancer while reducing side effects. Participants also r…

This study followed 354 men with low- to intermediate-risk prostate cancer who chose to freeze only the cancerous half of their prostate (hemi-gland cryoablation). Researchers tracked how well the treatment controlled the cancer and how it affected urinary function and quality of…

This study tested whether a shorter course of higher-dose radiation (hypofractionated) works as well as standard radiation after prostate removal in 296 men with prostate cancer. The main focus was on quality of life, especially urinary and bowel function. The goal is to find a t…

This study tested a new X-ray monitoring technique (KIM) during prostate cancer radiation therapy. The goal was to see if it helps doctors aim more precisely at the tumor while reducing harm to healthy tissue. 49 men with low- or intermediate-risk prostate cancer took part. The a…

This study tested whether adding the drug niraparib to standard radiation and hormone therapy can help prevent high-risk prostate cancer from coming back. Niraparib blocks a protein that cancer cells use to repair their DNA, which may kill them. The trial enrolled 22 men with agg…

This study tested a new drug (BXCL701) combined with an immunotherapy (pembrolizumab) in 98 men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if the combination could shrink tumors or slow the disease. This is a disease control appr…

This study tested whether adding a radioactive drug (radium-223) to standard targeted radiation (SBRT) can delay cancer progression in men whose prostate cancer has returned in a few bone spots but hasn't yet become hormone-resistant. Twelve men participated, receiving either the…

This study compared two radiation therapy schedules for men with intermediate- or high-risk prostate cancer. One group received fewer, higher-dose radiation sessions (hypofractionated), while the other received standard daily doses. Both groups also received hormone therapy. The …

This study tested a drug called niraparib in 11 men with advanced prostate cancer that was no longer responding to hormone therapy but had recently been treated with platinum chemotherapy. The goal was to see if niraparib could keep the cancer from growing for at least 6 months. …

This study tested a new surgical clip called VasoClip, designed to hold blood vessels closed more securely during robotic surgery for prostate, kidney, or bladder cancer. Forty patients were randomly assigned to receive either the new clip or a standard clip. The goal was to see …

This pilot study tested whether a diet and exercise program could prevent or reduce metabolic side effects like insulin resistance and weight gain in 20 men with prostate cancer receiving hormone therapy and radiation. Participants followed dietary instructions and did aerobic an…

This study looked at a combination of two drugs, talazoparib and temozolomide, in 16 men with advanced prostate cancer that had spread and stopped responding to hormone therapy. The goal was to find the safest dose and see if the drugs could shrink tumors. The study was completed…

This study tested a new way to treat low-risk prostate cancer using MRI-guided laser ablation. Seven men with early-stage prostate cancer received the treatment to see if it was safe and could successfully destroy tumors. The goal was to target only the cancer while avoiding side…

This study tested a new type of radiation therapy called DaRT seeds for men with prostate cancer. The goal was to see if it is safe and possible to place these tiny radioactive seeds directly into the tumor before surgery. Only one person took part, and the focus was on whether t…

This phase 2 trial tested a combination of testosterone and olaparib in 36 men with castration-resistant prostate cancer. The idea is that testosterone can cause DNA damage in cancer cells that have adapted to low testosterone, while olaparib blocks the cells' ability to repair t…

This early study tested whether adding a radioactive drug (177Lu-PSMA) to standard brachytherapy is safe and feasible for men whose prostate cancer returned after initial radiation. Only 3 men took part. The goal was to see if the combination could control cancer both in the pros…

This Phase 3 study tested a radioactive tracer called Copper Cu 64 PSMA I&T, given as an injection, to improve PET/CT scans in 235 men with prostate cancer that may have returned after initial treatment (surgery or radiation). The goal was to see how accurately the scan could det…

This study tested a fluorescent dye called IS-002 that makes prostate cancer cells glow under special lights during robotic surgery. Fifty-nine men with prostate cancer received the dye before surgery, and surgeons used a special camera to see the glowing areas. The goal was to s…

This study tested whether a very low dose of apalutamide, taken for 3-4 weeks before prostate removal surgery, could lower PSA levels in 34 men with early-stage prostate cancer. The goal was to see if the drug blocks testosterone's effect on cancer growth. If it works, it might o…

This study tested whether a supplement made from muscadine grapes could reduce fatigue and improve quality of life in 106 men with prostate cancer who were already receiving hormone therapy (androgen deprivation therapy). Participants took either the grape extract or a placebo fo…

This early-phase trial tested a dye called Illuminare-1 that makes nerves glow during prostate cancer surgery. The goal was to find a safe dose that helps surgeons avoid damaging nerves, which can cause side effects like incontinence. The study involved 41 men undergoing standard…

This early-phase trial tested a precise, high-dose radiation technique called stereotactic body radiotherapy (SBRT) in 42 patients with breast, lung, or prostate cancer that had spread to several places in the body. The main goal was to find the safest dose and check for side eff…

This study looked at how an experimental drug called SHR3680 affects the way the body processes three other common drugs: digoxin, rosuvastatin, and metformin. Thirty-six men with prostate cancer took SHR3680 along with these drugs to see if there were any interactions. The goal …

This study looked at how DNA from tumors changes in the blood before, during, and after surgery for breast, prostate, or colon cancer. Thirty adults having curative surgery provided blood samples to measure these DNA levels. The goal was to understand the natural pattern of DNA c…

This study looked at whether giving prostate cancer survivors more detailed survivorship care plans helps them get better follow-up care for heart health. The study involved 550 men who had radiation and hormone therapy, which can increase risks for diabetes and heart problems. R…